miRNA profiles in serum and CSF of Parkinson's and Alzheimer's patients

We profiled the miRNA contents from cerebrospinal fluid and serum (using next generation sequencing) from postmortem patients diagnosed with Alzheimer's or Parkinson's disease, and neurologically normal controls. All biofluids were cell-free and patient matched, there was one cerebrospinal fluid and one serum sample from each of 70 patients with Alzheimer's disease, 67 patients with Parkinson's disease and 78 age-similar controls. We correlated the miRNA changes with measurements of neuropathology such as plaques, tangles and Lewy bodies.]]> For inclusion in the study, the participants had to be diagnosed with Alzheimer's disease or Parkinson's disease based on postmortem neuropathological criteria or to be neuropathologically normal.]]>